22 results about "Meningioma" patented technology

The invention discloses a positive ion saliva marker related to brain glioma and meningioma and application of the positive ion saliva marker, and relates to the field of biological medicine. The positive ion saliva marker is prepared from one or more of L-arabitol, 20-hydroxyarachidonic acid, sulfonate and palm oil acylethanolamide. The invention provides a kit which is used for detecting positive ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.

The application discloses a double-branch Raio gating graph aggregation multi-modal meningioma segmentation method, belongs to the cross technical field of computer vision and medical image processing, is used for meningioma segmentation, and comprises the following steps: preparing a data set, constructing a deep neural network model, and performing neural network training; inputting the data set into the trained deep neural network model; first inputting a double-branch multi-modal input module to output a multi-modal fusion feature tensor; then inputting the multi-modal fusion feature tensor into a hierarchical Swin Transformer encoder to output three-dimensional segmentation masks of enhanced tumors, tumor cores and whole tumor regions of meningioma. Through double-branch multi-modal input fusion, hierarchical Swin Transformer coding, edge perception modulation and Laplace gating graph aggregation, high-precision three-dimensional segmentation of enhanced tumors, tumor cores and whole tumor regions of meningioma is realized.

The present disclosure pertains to a method of predicting a molecular subtype of a tumor of a subject by (1) receiving preoperative imaging data of the tumor; (2) extracting one or more features of the imaging data; and (3) correlating the extracted features of the imaging data to a molecular subtype of the tumor. The methods may also include steps of outputting the molecular subtype of the tumor and implementing a treatment decision. The present disclosure also pertain to a computing device and a diagnostic test for predicting a molecular subtype of a tumor of a subject in accordance with the aforementioned methods.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The invention discloses a positive ion saliva marker related to brain glioma and meningioma and application of the positive ion saliva marker, and relates to the field of biological medicine. The positive ion saliva marker is prepared from one or more of N1, N12-diacetyl spermine, N-capryloyl dihydrosphingosine and perindopril. The invention provides a kit which is used for detecting positive ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

The invention relates to a compound of formula (I), wherein, for example, - Z is representing a group (II), wherein R5 is representing NR6R7 group and wherein R6 and R7 represent independently a hydrogen - R4 is representing a O-aryl ring, - X is representing a NR2R3 group, wherein R2 and R3 are independently hydrogen and a (C1- C10)alkyl group, - R1 is representing a group (III), for its use in the prevention or the treatment of one of the following brain cancers chosen among: glioblastoma, astrocytoma, oligodendroglioma, medulloblastoma, ependymoma, meningioma, pineoblastoma, or in the prevention or the treatment of epilepsies or infantile epilepsies.

The application discloses a dental plaque microbial marker related to brain glioma and meningioma and an application thereof, and belongs to the field of biological medicine. The dental plaque microbial marker comprises one or more of Prevotella shahii, Capnocytophaga gingivalis, Mycobacterium gordonae, Leptothrix oralis and Ottowia. The application provides a kit comprising detection reagents for detecting the relative abundance of the dental plaque microbial marker. The application provides a product for diagnosing brain glioma and a computer program product related to brain glioma and meningioma. The product provided by the application has good feasibility and accuracy, and can be used as a new idea and approach for distinguishing brain glioma and meningioma.

The invention discloses a negative ion saliva marker related to brain glioma and meningioma and application of the negative ion saliva marker, and relates to the field of biological medicine. The negative ion saliva marker is prepared from one or more of 1, 2-dioleoyl-sn-glycerol-3-phosphoric acid, N-acetyl-L-glutamic acid, arabitol, myristic acid, linolenic acid and hexanoic acid. The invention provides a kit, which is used for detecting negative ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.

The application discloses a meningioma automatic grading method based on multi-view image feature fusion, comprising the following steps: S1: for the model input end, the lesion image of Dicom format data is converted into PNG data without any image enhancement and data amplification processing, and is input into a multi-view image feature fusion model as three channels; S2: the full connection layer and the maximum pooling of ResNet are removed as the basic network of each view feature extraction, transfer learning is introduced, and a normalized attention module is added to the model to suppress the insignificant features of the related views, so that the best feature information of each view is extracted; S3: after the feature information extracted from each view is fused, the feature is re-extracted, and the interference information is further filtered, and the pre-training residual neural network model of the three different channels and the fusion network are used to compose the model, and the fusion model is trained in an end-to-end mode, so that the effect of accurately distinguishing low-grade meningioma and high-grade meningioma can be achieved.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The invention discloses a positive ion saliva metabolite marker related to meningioma, a product and application of the positive ion saliva metabolite marker, and relates to the field of biological medicine. The positive ion saliva metabolite marker is prepared from one or more of 1-palmitoyl-2-glutaryl phosphatidylcholine, 2, 3, 5-triiodobenzene alcohol, beta-estradiol, cortisol, N-acetylcadaverine, prilocaine, octadecanoic acid, sulfamethoxam and rimsulfuron. The invention provides a kit which is used for detecting positive ion saliva metabolite markers related to meningioma and comprises a specific detection reagent. In addition, the invention also provides a computer program product which is specially used for evaluating meningioma. The products have good feasibility and accuracy, the risk of meningioma can be effectively evaluated, and a brand new powerful tool is provided for clinical diagnosis.

The invention discloses human meningioma radiotherapy-resistant cell strains IOMM-Lee-RR and CH157-RR, which are preserved in the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC NO.C202527 and CCTCC NO.C202528, are radiotherapy-resistant cell strains obtained after the human meningioma cell strains IOMM-Lee and CH157 are subjected to no less than 10 times of X-ray accumulative irradiation and subculture respectively, have remarkable radiotherapy-resistant characteristics, and can be used for preparing radiotherapy-resistant cell strains for treating meningioma. And a foundation is provided for further research on screening of radiotherapy resistance related genes and radiotherapy resistance molecular mechanisms of human meningioma, screening of radiotherapy resistance targets and improvement of radiotherapy sensitivity.

The invention provides a method and a system for predicting the growth risk of accidental asymptomatic meningioma. The method comprises the following steps: acquiring baseline clinical data, iconomic semantic feature data and iconomic feature data of a patient suffering from accidental asymptomatic meningioma; dividing the patient queue into a training set, a verification set and a test set, screening independent prediction factors significantly related to tumor growth, training a random survival forest model based on the training set, and performing optimization and verification in the verification set and the test set to generate an optimal model for predicting the individualized time-dependent growth risk; and inputting related data of a patient to be predicted into the optimal model, and outputting meningioma growth risk assessment results at different time points in the future. According to the invention, the technical problem that a patient with primary asymptomatic meningioma lacks an individualized natural growth trend prediction tool is solved.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.

The present application relates to a meningioma infiltration boundary resection strategy optimization method, which uses the stress and strain response difference during intraoperative tissue traction and suction operation to mark the biomechanical abnormal area in space; constructs a mechanical residual atlas; extracts the local tissue compliance critical point as the physiological landmark of the infiltration boundary; identifies the high adaptability channel in the three-dimensional tissue atlas; makes partition modeling for the structural impedance of different regions; constructs a boundary evolution stability hot area map, maps the boundary prediction result back to the current operation scene, and is used to judge whether the resection range needs to be expanded; after each tissue stripping or resection, the corresponding regional tissue deformation rate, blood supply flow rate and temperature diffusion mode indicators are collected as the reflection of the intraoperative boundary stress response, which is used to evaluate whether the high-risk area has been touched by the resection behavior; once the boundary stress index exceeds the preset threshold, the system freezes the path segment, calculates the alternative path, improves the accuracy of boundary identification, and reduces the damage to the functional area and the recurrence risk.

The application discloses application of RPL27A gene and / or RPL27A protein in preparation of a meningioma treatment drug. The application provides a new meningioma treatment target, and the RPL27A has a significant anti-meningioma function, can inhibit occurrence, development and metastasis of meningioma, and has wide clinical application value for development of a new meningioma diagnosis marker and a treatment drug.

The invention provides application of a compound in preparation of a medicine for inhibiting G3BPs, and belongs to the technical field of biological medicine. The medicine is used for treating tumors, neurodegenerative diseases or virus infection; the tumors comprise any one or a combination of lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, pancreatic cancer, cervical cancer, skin cancer, osteosarcoma, liposarcoma, smooth muscle sarcoma, leukemia, lymphoma, multiple myeloma, glioma, meningioma, testicular cancer, endometrial cancer, cervical cancer, ovarian cancer, melanoma, thyroid cancer, kidney cancer or bladder cancer. When the compound shown in the formula (I) is combined with different anti-tumor drugs in various tumor cells, the sensitivity of the cells to the anti-tumor drugs can be improved, so that the drug resistance of the tumor cells is reduced.

The application discloses a meningioma Ki67 classification method based on multi-modal medical data, applied to the field of image processing, aiming at the image data, radiology data and radiomics data based on 3D MRI with multiple modes during meningioma Ki67 prediction, and the existing technology has the problem of too large calculation overhead during multi-modal fusion; the application significantly reduces the calculation complexity through iterative modal information fusion of structured latent space and cross attention mechanism. It effectively captures the complementary information between modes through dynamic weight distribution and iterative refinement, while suppressing redundant noise, avoiding the feature dilution problem caused by mode length difference or simple superposition in the traditional splicing method; the compact representation of the latent space forces different modes to interact efficiently in the shared dimension, not only retaining the key patterns of cross-modal correlation, but also adaptively filtering irrelevant content through the attention mechanism, thereby achieving a better balance in information density and semantic consistency, especially suitable for processing real scenes with mode imbalance or partial loss.

The present invention relates to a compound 2-hydroxy-octadecene-9-cis-acid for use in the treatment of tumor pathology, the tumor pathologies include grade IV glioblastoma with natural IDH, grade 3 glioma, embryonic tumor, pituitary tumor, meningioma, vascular epidermis cytoma, vascular blastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, umbilical urinary duct cancer, bladder adenocarcinoma, and esophageal cancer, as well as for the treatment of neuropathic pain. The neuropathic pain is caused by diabetic peripheral neuropathy, spinal cord injury, post-herpes zoster neuralgia, a chemotherapeutic agent, an antitumor agent, cancer, fibromyalgia or hepatitis. The present invention also relates to a pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-acid, and a pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-acid.

The invention discloses a negative ion saliva marker related to brain glioma and meningioma and application of the negative ion saliva marker, and relates to the field of biological medicine. The negative ion saliva marker comprises 2-(4-chloro-2-methyl phenoxy) acetic acid and / or quillaic acid. The invention provides a kit, which is used for detecting negative ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.